First, we compared AKT protein expression in samples from patients with FLT3-ITD AML pre- and post-treatment with mitoxantrone-liposomes, and found increased expression of the AKT protein post-treatment (Fig. 3c-d). The gene discussed is AKT1; the disease is acute myeloid leukemia.